MYP_096442
Basic Information
Ropeginterferon alfa-2b
Anticancer
Immunology Immune modulation Immunomodulatory activity
Therapeutic / Biomedical activity Enzyme replacement therapy
Standard
166 amino acids
C865H1360N230O256S9
Standard
Sequence
PCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Physicochemical Analysis
19366.02 Da
5.99
-1.78
-2.10
-0.0107
-0.35
0.62
-0.04
53.22
85.18
0.1024
18450.00
18700.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
7900.41
-76.85
278.0
266.0
656.0
1360.0
28.0
181.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0342027 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Interferon
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
PEGylation, Lipidation
Bio-Activity Profile
Immunomodulatory Enzyme replacement
Ropeginterferon alfa-2b administered to polycythemia vera patients over a dose range of 100-500 µg has a half-life of approximately seven days.[L39170]
RECORD: Rec_0379953 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Interferon
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
PEGylation, Lipidation
Bio-Activity Profile
Anticancer Immunomodulatory
Ropeginterferon alfa-2b administered to polycythemia vera patients over a dose range of 100-500 µg has a half-life of approximately seven days.[L39170]
RECORD: Rec_0386909 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
Interferon
32630
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
PEGylation, Lipidation
Bio-Activity Profile
Immunomodulatory
Ropeginterferon alfa-2b administered to polycythemia vera patients over a dose range of 100-500 µg has a half-life of approximately seven days.[L39170]